Literature DB >> 19642006

Hypothesis: neoplasms in myotonic dystrophy.

Christine M Mueller1, James E Hilbert, William Martens, Charles A Thornton, Richard T Moxley, Mark H Greene.   

Abstract

Tumorigenesis is a multi-step process due to an accumulation of genetic mutations in multiple genes in diverse pathways which ultimately lead to loss of control over cell growth. It is well known that inheritance of rare germline mutations in genes involved in tumorigenesis pathways confer high lifetime risk of neoplasia in affected individuals. Furthermore, a substantial number of multiple malformation syndromes include cancer susceptibility in their phenotype. Studies of the mechanisms underlying these inherited syndromes have added to the understanding of both normal development and the pathophysiology of carcinogenesis. Myotonic dystrophy (DM) represents a group of autosomal dominant, multisystemic diseases that share the clinical features of myotonia, muscle weakness, and early-onset cataracts. Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) result from unstable nucleotide repeat expansions in their respective genes. There have been multiple reports of tumors in individuals with DM, most commonly benign calcifying cutaneous tumors known as pilomatricomas. We provide a summary of the tumors reported in DM and a hypothesis for a possible mechanism of tumorigenesis. We hope to stimulate further study into the potential role of DM genes in tumorigenesis, and help define DM pathogenesis, and facilitate developing novel treatment modalities.

Entities:  

Mesh:

Year:  2009        PMID: 19642006      PMCID: PMC3110730          DOI: 10.1007/s10552-009-9395-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  113 in total

Review 1.  Clinical and molecular aspects of the myotonic dystrophies: a review.

Authors:  Laura Machuca-Tzili; David Brook; David Hilton-Jones
Journal:  Muscle Nerve       Date:  2005-07       Impact factor: 3.217

2.  Myotonic dystrophy and pilomatricomas: an unusual association.

Authors:  A Filla; A Perretti; F Barbieri; M Marolda; L Pelosi; M Delfino; M Corona
Journal:  Acta Neurol (Napoli)       Date:  1982-04

3.  Myotonic dystrophy and thymoma.

Authors:  L Carlin; J Biller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-09       Impact factor: 10.154

4.  [Myotonic dystrophy and thymoma associated with myasthenic behavior on electromyography].

Authors:  A Cánovas; E Rodríguez Illera; A Arizcun; C Riva; J Diego
Journal:  Rev Clin Esp       Date:  1981-03-31       Impact factor: 1.556

5.  Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy.

Authors:  Thai H Ho; Donnie Bundman; Dawna L Armstrong; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2005-04-20       Impact factor: 6.150

Review 6.  Lost in transcription: p21 repression, mechanisms, and consequences.

Authors:  Andrei L Gartel; Senthil K Radhakrishnan
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

7.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.

Authors:  Jeroen H Roelfsema; Stefan J White; Yavuz Ariyürek; Deborah Bartholdi; Dunja Niedrist; Francesco Papadia; Carlos A Bacino; Johan T den Dunnen; Gert-Jan B van Ommen; Martijn H Breuning; Raoul C Hennekam; Dorien J M Peters
Journal:  Am J Hum Genet       Date:  2005-02-10       Impact factor: 11.025

8.  Multiple familial pilomatricomas: a cutaneous marker for myotonic dystrophy.

Authors:  M Delfino; G Monfrecola; F Ayala; F Suppa; A Piccirillo
Journal:  Dermatologica       Date:  1985

9.  [Multiple pilomatrixomas as symptoms of Curschmann-Steinert myotonia dystrophica].

Authors:  U Runne; G N Chilf; J Zentner
Journal:  Hautarzt       Date:  1982-05       Impact factor: 0.751

10.  Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).

Authors:  Liliana Montella; Michele Caraglia; Raffaele Addeo; Raffaele Costanzo; Vincenzo Faiola; Alberto Abbruzzese; Salvatore Del Prete
Journal:  Ann Hematol       Date:  2004-03-23       Impact factor: 3.673

View more
  30 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

3.  Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis.

Authors:  Jose I Emparanza; Adolfo López de Munain; Mark H Greene; Ander Matheu; Roberto Fernández-Torrón; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2018-10       Impact factor: 3.217

4.  Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Authors:  S M Gadalla; J E Hilbert; W B Martens; S Givens; R T Moxley; M H Greene
Journal:  Eur J Neurol       Date:  2017-03-20       Impact factor: 6.089

5.  Benign and malignant tumors in the UK myotonic dystrophy patient registry.

Authors:  Rotana Alsaggaf; Youjin Wang; Chiara Marini-Bettolo; Libby Wood; Nikoletta Nikolenko; Hanns Lochmüller; Mark H Greene; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2017-07-24       Impact factor: 3.217

6.  Imaging of the thymus in myotonic dystrophy type 1.

Authors:  Andrea Mignarri; Francesco Gentili; Francesco Masia; Angelo Genua; Silvia Cenciarelli; Paola Brunori; Maria Antonietta Mazzei; Alessandro Malandrini; Antonio Federico; Francesco Giuseppe Mazzei; Maria Teresa Dotti
Journal:  Neurol Sci       Date:  2017-11-25       Impact factor: 3.307

7.  Uveal Melanoma Associated With Myotonic Dystrophy: A Report of 6 Cases.

Authors:  Lauren A Dalvin; Carol L Shields; Jose S Pulido; Kareem Sioufi; Victoria Cohen; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

Review 8.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

9.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

10.  Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.

Authors:  Maria Laura Ester Bianchi; Emanuele Leoncini; Marcella Masciullo; Anna Modoni; Shahinaz M Gadalla; Roberto Massa; Emanuele Rastelli; Chiara Terracciano; Giovanni Antonini; Elisabetta Bucci; Antonio Petrucci; Sandro Costanzi; Massimo Santoro; Stefania Boccia; Gabriella Silvestri
Journal:  J Neurol       Date:  2016-01-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.